Safety and Efficacy of Filgotinib for Japanese Patients with RA and Inadequate Response to MTX: FINCH 1 52-Week Results and FINCH 4 48-Week Results.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac084
Abstract: OBJECTIVE To present safety and efficacy of the JAK1 preferential inhibitor filgotinib in Japanese patients with prior inadequate response (IR) to methotrexate (MTX) from a 52-week randomised controlled parent study (PS) and long-term extension (LTE)… read more here.
Keywords: finch week; rheumatology; safety; japanese patients ... See more keywords
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients.
Sign Up to like & getrecommendations! Published in 2019 at "AIDS"
DOI: 10.1097/qad.0000000000002463
Abstract: BACKGROUND Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10mg was investigated through 96 weeks in AMBER (NCT02431247). METHODS Treatment-naïve, HIV-1-positive adults (screening plasma viral load [VL]≥1000 copies/ml; CD4 count >50 cells/mm) were randomized (1:1) to D/C/F/TAF (N=362) or D/C… read more here.
Keywords: week results; emtricitabine tenofovir; darunavir; tenofovir ... See more keywords